Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

443 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A four-group urine risk classifier for predicting outcomes in patients with prostate cancer.
Connell SP, Yazbek-Hanna M, McCarthy F, Hurst R, Webb M, Curley H, Walker H, Mills R, Ball RY, Sanda MG, Pellegrini KL, Patil D, Perry AS, Schalken J, Pandha H, Whitaker H, Dennis N, Stuttle C, Mills IG, Guldvik I; Movember GAP1 Urine Biomarker Consortium; Parker C, Brewer DS, Cooper CS, Clark J. Connell SP, et al. Among authors: cooper cs. BJU Int. 2019 Oct;124(4):609-620. doi: 10.1111/bju.14811. Epub 2019 Jun 25. BJU Int. 2019. PMID: 31106513 Free PMC article.
Amplification and overexpression of E2F3 in human bladder cancer.
Feber A, Clark J, Goodwin G, Dodson AR, Smith PH, Fletcher A, Edwards S, Flohr P, Falconer A, Roe T, Kovacs G, Dennis N, Fisher C, Wooster R, Huddart R, Foster CS, Cooper CS. Feber A, et al. Among authors: cooper cs. Oncogene. 2004 Feb 26;23(8):1627-30. doi: 10.1038/sj.onc.1207274. Oncogene. 2004. PMID: 14716298
Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer.
Jhavar S, Brewer D, Edwards S, Kote-Jarai Z, Attard G, Clark J, Flohr P, Christmas T, Thompson A, Parker M, Shepherd C, Stenman UH, Marchbank T, Playford RJ, Woodhouse C, Ogden C, Fisher C, Kovacs G, Corbishley C, Jameson C, Norman A, De-Bono J, Bjartell A, Eeles R, Cooper CS. Jhavar S, et al. Among authors: cooper cs. BJU Int. 2009 May;103(9):1256-69. doi: 10.1111/j.1464-410X.2008.08200.x. Epub 2008 Nov 25. BJU Int. 2009. PMID: 19040532
ETS gene fusions in prostate cancer.
Clark JP, Cooper CS. Clark JP, et al. Among authors: cooper cs. Nat Rev Urol. 2009 Aug;6(8):429-39. doi: 10.1038/nrurol.2009.127. Nat Rev Urol. 2009. PMID: 19657377 Review.
A census of amplified and overexpressed human cancer genes.
Santarius T, Shipley J, Brewer D, Stratton MR, Cooper CS. Santarius T, et al. Among authors: cooper cs. Nat Rev Cancer. 2010 Jan;10(1):59-64. doi: 10.1038/nrc2771. Nat Rev Cancer. 2010. PMID: 20029424 Review.
Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalation.
Vergis R, Corbishley CM, Thomas K, Horwich A, Huddart R, Khoo V, Eeles R, Sydes MR, Cooper CS, Dearnaley D, Parker C. Vergis R, et al. Among authors: cooper cs. Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):35-41. doi: 10.1016/j.ijrobp.2009.07.1728. Epub 2010 Jan 21. Int J Radiat Oncol Biol Phys. 2010. PMID: 20092961 Clinical Trial.
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study.
Olmos D, Brewer D, Clark J, Danila DC, Parker C, Attard G, Fleisher M, Reid AH, Castro E, Sandhu SK, Barwell L, Oommen NB, Carreira S, Drake CG, Jones R, Cooper CS, Scher HI, de Bono JS. Olmos D, et al. Among authors: cooper cs. Lancet Oncol. 2012 Nov;13(11):1114-24. doi: 10.1016/S1470-2045(12)70372-8. Epub 2012 Oct 9. Lancet Oncol. 2012. PMID: 23059046 Free PMC article.
443 results